CA2283231C - Vecteurs d'adenovirus contenant des elements heterologues regulateurs de transcription, et leur procede d'utilisation - Google Patents

Vecteurs d'adenovirus contenant des elements heterologues regulateurs de transcription, et leur procede d'utilisation Download PDF

Info

Publication number: CA2283231C
Authority: CA; Canada
Prior art keywords: tre; adenovirus; gene; cell; heterologous
Prior art date: 1997-03-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA002283231A

Other languages

English (en)

Other versions

CA2283231A1 (fr

Inventor

Daniel R. Henderson

De-Chao Yu

Henry G. Lamparski

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

CG Oncology Inc

Original Assignee

Cell Genesys Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-03-03

Filing date

1998-03-03

Publication date

2008-05-20

1998-03-02 Priority claimed from US09/033,556 external-priority patent/US6432700B1/en

1998-03-03 Application filed by Cell Genesys Inc filed Critical Cell Genesys Inc

1998-09-11 Publication of CA2283231A1 publication Critical patent/CA2283231A1/fr

2008-05-20 Application granted granted Critical

2008-05-20 Publication of CA2283231C publication Critical patent/CA2283231C/fr

2018-03-03 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

241000701161 unidentified adenovirus Species 0.000 title claims abstract description 403
239000013598 vector Substances 0.000 title claims abstract description 286
238000000034 method Methods 0.000 title abstract description 61
230000035897 transcription Effects 0.000 title description 56
238000013518 transcription Methods 0.000 title description 56
230000001105 regulatory effect Effects 0.000 title description 24
108700029229 Transcriptional Regulatory Elements Proteins 0.000 claims abstract description 403
108090000623 proteins and genes Proteins 0.000 claims abstract description 296
230000010076 replication Effects 0.000 claims abstract description 84
108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 44
230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims description 44
102100038358 Prostate-specific antigen Human genes 0.000 claims description 37
210000005267 prostate cell Anatomy 0.000 claims description 35
108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 25
102000012406 Carcinoembryonic Antigen Human genes 0.000 claims description 25
239000000203 mixture Substances 0.000 claims description 20
230000001472 cytotoxic effect Effects 0.000 claims description 17
108010042121 probasin Proteins 0.000 claims description 14
231100000433 cytotoxic Toxicity 0.000 claims description 13
230000009089 cytolysis Effects 0.000 claims description 9
206010057248 Cell death Diseases 0.000 claims description 7
101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 6
230000001225 therapeutic effect Effects 0.000 claims description 6
102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 4
239000000546 pharmaceutical excipient Substances 0.000 claims description 4
101710103262 Glandular kallikrein Proteins 0.000 claims description 3
102000057032 Tissue Kallikreins Human genes 0.000 claims description 3
108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 3
229940123373 Adenovirus E1A gene Drugs 0.000 claims description 2
102100031358 Urokinase-type plasminogen activator Human genes 0.000 claims 2
102000013529 alpha-Fetoproteins Human genes 0.000 claims 1
108010026331 alpha-Fetoproteins Proteins 0.000 claims 1
210000004027 cell Anatomy 0.000 abstract description 436
241000700605 Viruses Species 0.000 abstract description 76
102000040430 polynucleotide Human genes 0.000 abstract description 59
108091033319 polynucleotide Proteins 0.000 abstract description 59
239000002157 polynucleotide Substances 0.000 abstract description 59
231100000135 cytotoxicity Toxicity 0.000 abstract description 28
230000003013 cytotoxicity Effects 0.000 abstract description 26
108700019146 Transgenes Proteins 0.000 abstract description 15
210000005170 neoplastic cell Anatomy 0.000 abstract description 6
206010028980 Neoplasm Diseases 0.000 description 96
230000014509 gene expression Effects 0.000 description 78
241001135569 Human adenovirus 5 Species 0.000 description 60
229920001223 polyethylene glycol Polymers 0.000 description 60
239000003795 chemical substances by application Substances 0.000 description 54
150000007523 nucleic acids Chemical class 0.000 description 53
230000000873 masking effect Effects 0.000 description 52
102000039446 nucleic acids Human genes 0.000 description 52
108020004707 nucleic acids Proteins 0.000 description 52
102000004169 proteins and genes Human genes 0.000 description 50
239000002202 Polyethylene glycol Substances 0.000 description 49
239000003623 enhancer Substances 0.000 description 47
230000006870 function Effects 0.000 description 43
238000003752 polymerase chain reaction Methods 0.000 description 42
238000011144 upstream manufacturing Methods 0.000 description 42
230000000694 effects Effects 0.000 description 41
239000012634 fragment Substances 0.000 description 40
210000004881 tumor cell Anatomy 0.000 description 38
238000003556 assay Methods 0.000 description 37
239000013612 plasmid Substances 0.000 description 37
108010080146 androgen receptors Proteins 0.000 description 34
102100032187 Androgen receptor Human genes 0.000 description 32
208000015181 infectious disease Diseases 0.000 description 31
238000011282 treatment Methods 0.000 description 30
108700009124 Transcription Initiation Site Proteins 0.000 description 28
201000011510 cancer Diseases 0.000 description 27
108020004414 DNA Proteins 0.000 description 25
101150075174 E1B gene Proteins 0.000 description 24
206010060862 Prostate cancer Diseases 0.000 description 24
ABAFKQHGFDZEJO-UHFFFAOYSA-N 4,6,6-trimethylbicyclo[3.1.1]heptane-4-carbaldehyde Chemical compound C1C2C(C)(C)C1CCC2(C)C=O ABAFKQHGFDZEJO-UHFFFAOYSA-N 0.000 description 23
208000026310 Breast neoplasm Diseases 0.000 description 23
241000218633 Pinidae Species 0.000 description 23
206010006187 Breast cancer Diseases 0.000 description 22
108091026890 Coding region Proteins 0.000 description 21
239000002773 nucleotide Substances 0.000 description 20
125000003729 nucleotide group Chemical group 0.000 description 20
230000002103 transcriptional effect Effects 0.000 description 20
208000000236 Prostatic Neoplasms Diseases 0.000 description 19
201000010099 disease Diseases 0.000 description 19
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
210000001519 tissue Anatomy 0.000 description 19
239000003098 androgen Substances 0.000 description 18
230000027455 binding Effects 0.000 description 18
238000001727 in vivo Methods 0.000 description 18
239000000047 product Substances 0.000 description 18
230000003612 virological effect Effects 0.000 description 17
238000000338 in vitro Methods 0.000 description 16
210000002307 prostate Anatomy 0.000 description 16
238000006243 chemical reaction Methods 0.000 description 15
230000009826 neoplastic cell growth Effects 0.000 description 15
210000004185 liver Anatomy 0.000 description 14
210000002966 serum Anatomy 0.000 description 14
101150076489 B gene Proteins 0.000 description 13
108091028043 Nucleic acid sequence Proteins 0.000 description 13
108700008625 Reporter Genes Proteins 0.000 description 13
102000040945 Transcription factor Human genes 0.000 description 13
108091023040 Transcription factor Proteins 0.000 description 13
230000000120 cytopathologic effect Effects 0.000 description 13
230000001965 increasing effect Effects 0.000 description 13
230000029812 viral genome replication Effects 0.000 description 13
210000000481 breast Anatomy 0.000 description 12
210000004962 mammalian cell Anatomy 0.000 description 12
210000005260 human cell Anatomy 0.000 description 11
238000003780 insertion Methods 0.000 description 11
230000037431 insertion Effects 0.000 description 11
239000002245 particle Substances 0.000 description 11
239000003981 vehicle Substances 0.000 description 11
239000004971 Cross linker Substances 0.000 description 10
238000012217 deletion Methods 0.000 description 10
230000037430 deletion Effects 0.000 description 10
-1 for example Proteins 0.000 description 10
230000012010 growth Effects 0.000 description 10
206010073071 hepatocellular carcinoma Diseases 0.000 description 10
210000004924 lung microvascular endothelial cell Anatomy 0.000 description 10
230000035772 mutation Effects 0.000 description 10
238000012360 testing method Methods 0.000 description 10
239000012472 biological sample Substances 0.000 description 9
238000012512 characterization method Methods 0.000 description 9
238000010276 construction Methods 0.000 description 9
230000001276 controlling effect Effects 0.000 description 9
229920001477 hydrophilic polymer Polymers 0.000 description 9
208000023958 prostate neoplasm Diseases 0.000 description 9
101001050577 Homo sapiens Kinesin-like protein KIF2A Proteins 0.000 description 8
102100023426 Kinesin-like protein KIF2A Human genes 0.000 description 8
102000003855 L-lactate dehydrogenase Human genes 0.000 description 8
108700023483 L-lactate dehydrogenases Proteins 0.000 description 8
108091034117 Oligonucleotide Proteins 0.000 description 8
230000030833 cell death Effects 0.000 description 8
238000004132 cross linking Methods 0.000 description 8
238000002474 experimental method Methods 0.000 description 8
208000020816 lung neoplasm Diseases 0.000 description 8
230000003211 malignant effect Effects 0.000 description 8
108020004999 messenger RNA Proteins 0.000 description 8
206010027476 Metastases Diseases 0.000 description 7
241000699670 Mus sp. Species 0.000 description 7
206010061535 Ovarian neoplasm Diseases 0.000 description 7
239000000872 buffer Substances 0.000 description 7
238000002744 homologous recombination Methods 0.000 description 7
230000006801 homologous recombination Effects 0.000 description 7
230000002458 infectious effect Effects 0.000 description 7
238000004519 manufacturing process Methods 0.000 description 7
230000004048 modification Effects 0.000 description 7
238000012986 modification Methods 0.000 description 7
108090000765 processed proteins & peptides Proteins 0.000 description 7
201000001514 prostate carcinoma Diseases 0.000 description 7
230000009467 reduction Effects 0.000 description 7
239000000523 sample Substances 0.000 description 7
230000003584 silencer Effects 0.000 description 7
101710197337 Adenovirus death protein Proteins 0.000 description 6
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
150000001413 amino acids Chemical class 0.000 description 6
208000029742 colonic neoplasm Diseases 0.000 description 6
238000011161 development Methods 0.000 description 6
230000018109 developmental process Effects 0.000 description 6
230000028993 immune response Effects 0.000 description 6
230000001939 inductive effect Effects 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
239000002502 liposome Substances 0.000 description 6
230000001404 mediated effect Effects 0.000 description 6
230000006320 pegylation Effects 0.000 description 6
238000010188 recombinant method Methods 0.000 description 6
108091008146 restriction endonucleases Proteins 0.000 description 6
239000007787 solid Substances 0.000 description 6
239000000126 substance Substances 0.000 description 6
239000006228 supernatant Substances 0.000 description 6
238000001890 transfection Methods 0.000 description 6
238000012546 transfer Methods 0.000 description 6
230000004614 tumor growth Effects 0.000 description 6
108090000565 Capsid Proteins Proteins 0.000 description 5
102100023321 Ceruloplasmin Human genes 0.000 description 5
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 5
206010009944 Colon cancer Diseases 0.000 description 5
101710145505 Fiber protein Proteins 0.000 description 5
108700028146 Genetic Enhancer Elements Proteins 0.000 description 5
108700039691 Genetic Promoter Regions Proteins 0.000 description 5
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 5
108700026244 Open Reading Frames Proteins 0.000 description 5
238000002105 Southern blotting Methods 0.000 description 5
208000005718 Stomach Neoplasms Diseases 0.000 description 5
101150055123 afp gene Proteins 0.000 description 5
230000004075 alteration Effects 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
230000002238 attenuated effect Effects 0.000 description 5
230000022534 cell killing Effects 0.000 description 5
230000001413 cellular effect Effects 0.000 description 5
238000002512 chemotherapy Methods 0.000 description 5
210000001072 colon Anatomy 0.000 description 5
230000000295 complement effect Effects 0.000 description 5
239000003431 cross linking reagent Substances 0.000 description 5
230000034994 death Effects 0.000 description 5
231100000517 death Toxicity 0.000 description 5
230000002950 deficient Effects 0.000 description 5
238000010586 diagram Methods 0.000 description 5
230000029087 digestion Effects 0.000 description 5
231100000844 hepatocellular carcinoma Toxicity 0.000 description 5
239000003550 marker Substances 0.000 description 5
230000009401 metastasis Effects 0.000 description 5
238000012544 monitoring process Methods 0.000 description 5
230000002018 overexpression Effects 0.000 description 5
238000004806 packaging method and process Methods 0.000 description 5
238000011160 research Methods 0.000 description 5
238000012552 review Methods 0.000 description 5
210000002784 stomach Anatomy 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
238000010361 transduction Methods 0.000 description 5
230000026683 transduction Effects 0.000 description 5
230000014616 translation Effects 0.000 description 5
230000004543 DNA replication Effects 0.000 description 4
238000002965 ELISA Methods 0.000 description 4
101710094396 Hexon protein Proteins 0.000 description 4
206010058467 Lung neoplasm malignant Diseases 0.000 description 4
241000124008 Mammalia Species 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
102100034256 Mucin-1 Human genes 0.000 description 4
108010063954 Mucins Proteins 0.000 description 4
206010061902 Pancreatic neoplasm Diseases 0.000 description 4
102000004504 Urokinase Plasminogen Activator Receptors Human genes 0.000 description 4
108010042352 Urokinase Plasminogen Activator Receptors Proteins 0.000 description 4
108020005202 Viral DNA Proteins 0.000 description 4
108010067390 Viral Proteins Proteins 0.000 description 4
230000004913 activation Effects 0.000 description 4
238000007792 addition Methods 0.000 description 4
208000009956 adenocarcinoma Diseases 0.000 description 4
239000000427 antigen Substances 0.000 description 4
108091007433 antigens Proteins 0.000 description 4
102000036639 antigens Human genes 0.000 description 4
238000013459 approach Methods 0.000 description 4
238000001574 biopsy Methods 0.000 description 4
230000006037 cell lysis Effects 0.000 description 4
239000002771 cell marker Substances 0.000 description 4
230000008859 change Effects 0.000 description 4
230000004087 circulation Effects 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
230000001461 cytolytic effect Effects 0.000 description 4
230000007423 decrease Effects 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
238000001514 detection method Methods 0.000 description 4
239000003814 drug Substances 0.000 description 4
108700020302 erbB-2 Genes Proteins 0.000 description 4
238000001415 gene therapy Methods 0.000 description 4
230000002068 genetic effect Effects 0.000 description 4
230000002209 hydrophobic effect Effects 0.000 description 4
230000005847 immunogenicity Effects 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
238000004255 ion exchange chromatography Methods 0.000 description 4
230000000670 limiting effect Effects 0.000 description 4
201000005202 lung cancer Diseases 0.000 description 4
238000011275 oncology therapy Methods 0.000 description 4
239000008194 pharmaceutical composition Substances 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
229920001184 polypeptide Polymers 0.000 description 4
230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
230000002441 reversible effect Effects 0.000 description 4
238000012289 standard assay Methods 0.000 description 4
235000000346 sugar Nutrition 0.000 description 4
238000012384 transportation and delivery Methods 0.000 description 4
108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
108020005029 5' Flanking Region Proteins 0.000 description 3
206010004446 Benign prostatic hyperplasia Diseases 0.000 description 3
101150045267 CEA gene Proteins 0.000 description 3
201000009030 Carcinoma Diseases 0.000 description 3
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
101000848653 Homo sapiens Tripartite motif-containing protein 26 Proteins 0.000 description 3
108010008707 Mucin-1 Proteins 0.000 description 3
102000015728 Mucins Human genes 0.000 description 3
206010033128 Ovarian cancer Diseases 0.000 description 3
208000004403 Prostatic Hyperplasia Diseases 0.000 description 3
108091027981 Response element Proteins 0.000 description 3
108700026226 TATA Box Proteins 0.000 description 3
108700005077 Viral Genes Proteins 0.000 description 3
150000001412 amines Chemical class 0.000 description 3
229940030486 androgens Drugs 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
230000008901 benefit Effects 0.000 description 3
201000008275 breast carcinoma Diseases 0.000 description 3
SNCZNSNPXMPCGN-UHFFFAOYSA-N butanediamide Chemical compound NC(=O)CCC(N)=O SNCZNSNPXMPCGN-UHFFFAOYSA-N 0.000 description 3
125000002091 cationic group Chemical group 0.000 description 3
230000004663 cell proliferation Effects 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
229940079593 drug Drugs 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
210000003527 eukaryotic cell Anatomy 0.000 description 3
230000002496 gastric effect Effects 0.000 description 3
239000005556 hormone Substances 0.000 description 3
229940088597 hormone Drugs 0.000 description 3
102000046101 human AFP Human genes 0.000 description 3
230000006698 induction Effects 0.000 description 3
230000003993 interaction Effects 0.000 description 3
210000005229 liver cell Anatomy 0.000 description 3
208000014018 liver neoplasm Diseases 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
238000013507 mapping Methods 0.000 description 3
230000037230 mobility Effects 0.000 description 3
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
230000006798 recombination Effects 0.000 description 3
238000005215 recombination Methods 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000003362 replicative effect Effects 0.000 description 3
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
230000004565 tumor cell growth Effects 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
238000010600 3H thymidine incorporation assay Methods 0.000 description 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
108010087905 Adenovirus E1B Proteins Proteins 0.000 description 2
OPZJWMJPCNNZNT-DCAQKATOSA-N Ala-Leu-Met Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)O)N OPZJWMJPCNNZNT-DCAQKATOSA-N 0.000 description 2
FFZJHQODAYHGPO-KZVJFYERSA-N Ala-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N FFZJHQODAYHGPO-KZVJFYERSA-N 0.000 description 2
102100027211 Albumin Human genes 0.000 description 2
108010088751 Albumins Proteins 0.000 description 2
SGYSTDWPNPKJPP-GUBZILKMSA-N Arg-Ala-Arg Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SGYSTDWPNPKJPP-GUBZILKMSA-N 0.000 description 2
ZTKHZAXGTFXUDD-VEVYYDQMSA-N Arg-Asn-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZTKHZAXGTFXUDD-VEVYYDQMSA-N 0.000 description 2
101000765604 Bacillus subtilis (strain 168) FlaA locus 22.9 kDa protein Proteins 0.000 description 2
101000964402 Caldicellulosiruptor saccharolyticus Uncharacterized protein in xynC 3'region Proteins 0.000 description 2
102000053642 Catalytic RNA Human genes 0.000 description 2
108090000994 Catalytic RNA Proteins 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
208000001333 Colorectal Neoplasms Diseases 0.000 description 2
GGRDJANMZPGMNS-CIUDSAMLSA-N Cys-Ser-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O GGRDJANMZPGMNS-CIUDSAMLSA-N 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
108010053187 Diphtheria Toxin Proteins 0.000 description 2
102000016607 Diphtheria Toxin Human genes 0.000 description 2
108010093502 E2F Transcription Factors Proteins 0.000 description 2
102000001388 E2F Transcription Factors Human genes 0.000 description 2
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
208000009889 Herpes Simplex Diseases 0.000 description 2
KYMUEAZVLPRVAE-GUBZILKMSA-N His-Asn-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O KYMUEAZVLPRVAE-GUBZILKMSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
KBHYLOIVRVBBEB-JBDRJPRFSA-N Ile-Cys-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)O)N KBHYLOIVRVBBEB-JBDRJPRFSA-N 0.000 description 2
QZZIBQZLWBOOJH-PEDHHIEDSA-N Ile-Ile-Val Chemical compound N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)O QZZIBQZLWBOOJH-PEDHHIEDSA-N 0.000 description 2
206010061598 Immunodeficiency Diseases 0.000 description 2
102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 2
101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 2
HGCNKOLVKRAVHD-UHFFFAOYSA-N L-Met-L-Phe Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 HGCNKOLVKRAVHD-UHFFFAOYSA-N 0.000 description 2
WGNOPSQMIQERPK-GARJFASQSA-N Leu-Asn-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N WGNOPSQMIQERPK-GARJFASQSA-N 0.000 description 2
WGNOPSQMIQERPK-UHFFFAOYSA-N Leu-Asn-Pro Natural products CC(C)CC(N)C(=O)NC(CC(=O)N)C(=O)N1CCCC1C(=O)O WGNOPSQMIQERPK-UHFFFAOYSA-N 0.000 description 2
ULXYQAJWJGLCNR-YUMQZZPRSA-N Leu-Asp-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O ULXYQAJWJGLCNR-YUMQZZPRSA-N 0.000 description 2
SEMUSFOBZGKBGW-YTFOTSKYSA-N Leu-Ile-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O SEMUSFOBZGKBGW-YTFOTSKYSA-N 0.000 description 2
JNDYEOUZBLOVOF-AVGNSLFASA-N Leu-Leu-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O JNDYEOUZBLOVOF-AVGNSLFASA-N 0.000 description 2
JLWZLIQRYCTYBD-IHRRRGAJSA-N Leu-Lys-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JLWZLIQRYCTYBD-IHRRRGAJSA-N 0.000 description 2
RTIRBWJPYJYTLO-MELADBBJSA-N Leu-Lys-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)O)N RTIRBWJPYJYTLO-MELADBBJSA-N 0.000 description 2
108060001084 Luciferase Proteins 0.000 description 2
239000005089 Luciferase Substances 0.000 description 2
101000977779 Lymantria dispar multicapsid nuclear polyhedrosis virus Uncharacterized 33.9 kDa protein in PE 3'region Proteins 0.000 description 2
YWJQHDDBFAXNIR-MXAVVETBSA-N Lys-Ile-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCCCN)N YWJQHDDBFAXNIR-MXAVVETBSA-N 0.000 description 2
CIIJWIAORKTXAH-FJXKBIBVSA-N Met-Thr-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O CIIJWIAORKTXAH-FJXKBIBVSA-N 0.000 description 2
OOXVBECOTYHTCK-WDSOQIARSA-N Met-Trp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCSC)N OOXVBECOTYHTCK-WDSOQIARSA-N 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
101100346932 Mus musculus Muc1 gene Proteins 0.000 description 2
101000827630 Narcissus mosaic virus Uncharacterized 10 kDa protein Proteins 0.000 description 2
206010029096 Neoplasm prostate Diseases 0.000 description 2
DXWNFNOPBYAFRM-IHRRRGAJSA-N Phe-Val-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N DXWNFNOPBYAFRM-IHRRRGAJSA-N 0.000 description 2
108010039918 Polylysine Proteins 0.000 description 2
DWPXHLIBFQLKLK-CYDGBPFRSA-N Pro-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 DWPXHLIBFQLKLK-CYDGBPFRSA-N 0.000 description 2
206010071019 Prostatic dysplasia Diseases 0.000 description 2
239000004365 Protease Substances 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
FLMYSKVSDVHLEW-SVSWQMSJSA-N Ser-Thr-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FLMYSKVSDVHLEW-SVSWQMSJSA-N 0.000 description 2
101710172711 Structural protein Proteins 0.000 description 2
108010044281 TATA-Box Binding Protein Proteins 0.000 description 2
102000006467 TATA-Box Binding Protein Human genes 0.000 description 2
DCLBXIWHLVEPMQ-JRQIVUDYSA-N Thr-Asp-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 DCLBXIWHLVEPMQ-JRQIVUDYSA-N 0.000 description 2
102100024026 Transcription factor E2F1 Human genes 0.000 description 2
CRWOSTCODDFEKZ-HRCADAONSA-N Tyr-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)O CRWOSTCODDFEKZ-HRCADAONSA-N 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
230000001594 aberrant effect Effects 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
239000002253 acid Substances 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
102000001307 androgen receptors Human genes 0.000 description 2
238000000137 annealing Methods 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
108010029539 arginyl-prolyl-proline Proteins 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
230000000981 bystander Effects 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
244000309466 calf Species 0.000 description 2
208000035269 cancer or benign tumor Diseases 0.000 description 2
210000000234 capsid Anatomy 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
238000010382 chemical cross-linking Methods 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
230000010405 clearance mechanism Effects 0.000 description 2
238000010367 cloning Methods 0.000 description 2
230000001010 compromised effect Effects 0.000 description 2
230000001086 cytosolic effect Effects 0.000 description 2
229940127089 cytotoxic agent Drugs 0.000 description 2
230000007547 defect Effects 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
239000012636 effector Substances 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
210000003038 endothelium Anatomy 0.000 description 2
210000000981 epithelium Anatomy 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
239000000284 extract Substances 0.000 description 2
239000000835 fiber Substances 0.000 description 2
XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 2
229960004413 flucytosine Drugs 0.000 description 2
229960002949 fluorouracil Drugs 0.000 description 2
206010017758 gastric cancer Diseases 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
238000010353 genetic engineering Methods 0.000 description 2
230000005745 host immune response Effects 0.000 description 2
102000051957 human ERBB2 Human genes 0.000 description 2
125000001165 hydrophobic group Chemical group 0.000 description 2
206010020718 hyperplasia Diseases 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
230000006872 improvement Effects 0.000 description 2
239000000411 inducer Substances 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
238000005342 ion exchange Methods 0.000 description 2
108010044374 isoleucyl-tyrosine Proteins 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
108010090333 leucyl-lysyl-proline Proteins 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
238000001638 lipofection Methods 0.000 description 2
201000007270 liver cancer Diseases 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
238000007726 management method Methods 0.000 description 2
239000002609 medium Substances 0.000 description 2
206010061289 metastatic neoplasm Diseases 0.000 description 2
238000002156 mixing Methods 0.000 description 2
KQTSOJHOCCWAEH-UHFFFAOYSA-N n'-(2,5-dioxopyrrolidin-1-yl)butanediamide Chemical compound NC(=O)CCC(=O)NN1C(=O)CCC1=O KQTSOJHOCCWAEH-UHFFFAOYSA-N 0.000 description 2
230000003472 neutralizing effect Effects 0.000 description 2
239000003921 oil Substances 0.000 description 2
238000002515 oligonucleotide synthesis Methods 0.000 description 2
230000002611 ovarian Effects 0.000 description 2
201000002528 pancreatic cancer Diseases 0.000 description 2
208000008443 pancreatic carcinoma Diseases 0.000 description 2
239000003182 parenteral nutrition solution Substances 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
229920000656 polylysine Polymers 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
230000008569 process Effects 0.000 description 2
229940002612 prodrug Drugs 0.000 description 2
239000000651 prodrug Substances 0.000 description 2
238000004393 prognosis Methods 0.000 description 2
230000000644 propagated effect Effects 0.000 description 2
230000001902 propagating effect Effects 0.000 description 2
238000001243 protein synthesis Methods 0.000 description 2
238000011472 radical prostatectomy Methods 0.000 description 2
238000001959 radiotherapy Methods 0.000 description 2
230000008707 rearrangement Effects 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
238000002271 resection Methods 0.000 description 2
108091092562 ribozyme Proteins 0.000 description 2
238000002741 site-directed mutagenesis Methods 0.000 description 2
230000007928 solubilization Effects 0.000 description 2
238000005063 solubilization Methods 0.000 description 2
239000000243 solution Substances 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
230000006641 stabilisation Effects 0.000 description 2
238000011105 stabilization Methods 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000002194 synthesizing effect Effects 0.000 description 2
230000001839 systemic circulation Effects 0.000 description 2
108010033670 threonyl-aspartyl-tyrosine Proteins 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
230000005758 transcription activity Effects 0.000 description 2
238000003151 transfection method Methods 0.000 description 2
238000013519 translation Methods 0.000 description 2
230000032258 transport Effects 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
230000010415 tropism Effects 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
WROAZRATAZZDRS-UHFFFAOYSA-N (2,3,4-trichlorophenyl) hydrogen carbonate Chemical class OC(=O)OC1=CC=C(Cl)C(Cl)=C1Cl WROAZRATAZZDRS-UHFFFAOYSA-N 0.000 description 1
JPNBVWIRDQVGAC-UHFFFAOYSA-N (2-nitrophenyl) hydrogen carbonate Chemical class OC(=O)OC1=CC=CC=C1[N+]([O-])=O JPNBVWIRDQVGAC-UHFFFAOYSA-N 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
YQNRVGJCPCNMKT-LFVJCYFKSA-N 2-[(e)-[[2-(4-benzylpiperazin-1-ium-1-yl)acetyl]hydrazinylidene]methyl]-6-prop-2-enylphenolate Chemical compound [O-]C1=C(CC=C)C=CC=C1\C=N\NC(=O)C[NH+]1CCN(CC=2C=CC=CC=2)CC1 YQNRVGJCPCNMKT-LFVJCYFKSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical compound C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 description 1
QXZGLTYKKZKGLN-UHFFFAOYSA-N 4-(2,5-dioxopyrrolidin-1-yl)oxy-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)ON1C(=O)CCC1=O QXZGLTYKKZKGLN-UHFFFAOYSA-N 0.000 description 1
108020003589 5' Untranslated Regions Proteins 0.000 description 1
FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
108010066676 Abrin Proteins 0.000 description 1
102000013563 Acid Phosphatase Human genes 0.000 description 1
108010051457 Acid Phosphatase Proteins 0.000 description 1
101000787132 Acidithiobacillus ferridurans Uncharacterized 8.2 kDa protein in mobL 3'region Proteins 0.000 description 1
101000827262 Acidithiobacillus ferrooxidans Uncharacterized 18.9 kDa protein in mobE 3'region Proteins 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 1
108010024878 Adenovirus E1A Proteins Proteins 0.000 description 1
108010056962 Adenovirus E4 Proteins Proteins 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
HHRAXZAYZFFRAM-CIUDSAMLSA-N Ala-Leu-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O HHRAXZAYZFFRAM-CIUDSAMLSA-N 0.000 description 1
IHMCQESUJVZTKW-UBHSHLNASA-N Ala-Phe-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CC1=CC=CC=C1 IHMCQESUJVZTKW-UBHSHLNASA-N 0.000 description 1
HOVPGJUNRLMIOZ-CIUDSAMLSA-N Ala-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N HOVPGJUNRLMIOZ-CIUDSAMLSA-N 0.000 description 1
WNHNMKOFKCHKKD-BFHQHQDPSA-N Ala-Thr-Gly Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O WNHNMKOFKCHKKD-BFHQHQDPSA-N 0.000 description 1
101000811747 Antithamnion sp. UPF0051 protein in atpA 3'region Proteins 0.000 description 1
FANGHKQYFPYDNB-UBHSHLNASA-N Asn-Asp-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N FANGHKQYFPYDNB-UBHSHLNASA-N 0.000 description 1
JLNFZLNDHONLND-GARJFASQSA-N Asn-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)N)N JLNFZLNDHONLND-GARJFASQSA-N 0.000 description 1
RNAQPBOOJRDICC-BPUTZDHNSA-N Asp-Met-Trp Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)N RNAQPBOOJRDICC-BPUTZDHNSA-N 0.000 description 1
XOASPVGNFAMYBD-WFBYXXMGSA-N Asp-Trp-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C)C(O)=O XOASPVGNFAMYBD-WFBYXXMGSA-N 0.000 description 1
241000271566 Aves Species 0.000 description 1
101000827607 Bacillus phage SPP1 Uncharacterized 8.5 kDa protein in GP2-GP6 intergenic region Proteins 0.000 description 1
101000961975 Bacillus thuringiensis Uncharacterized 13.4 kDa protein Proteins 0.000 description 1
206010004146 Basal cell carcinoma Diseases 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 1
101100462537 Caenorhabditis elegans pac-1 gene Proteins 0.000 description 1
101000964407 Caldicellulosiruptor saccharolyticus Uncharacterized 10.7 kDa protein in xynB 3'region Proteins 0.000 description 1
102000005367 Carboxypeptidases Human genes 0.000 description 1
108010006303 Carboxypeptidases Proteins 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
102100023804 Coagulation factor VII Human genes 0.000 description 1
206010061045 Colon neoplasm Diseases 0.000 description 1
206010010741 Conjunctivitis Diseases 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
102000000311 Cytosine Deaminase Human genes 0.000 description 1
108010080611 Cytosine Deaminase Proteins 0.000 description 1
102000004594 DNA Polymerase I Human genes 0.000 description 1
108010017826 DNA Polymerase I Proteins 0.000 description 1
102000052510 DNA-Binding Proteins Human genes 0.000 description 1
101710096438 DNA-binding protein Proteins 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
101150082674 E2 gene Proteins 0.000 description 1
101150066038 E4 gene Proteins 0.000 description 1
102000001301 EGF receptor Human genes 0.000 description 1
108060006698 EGF receptor Proteins 0.000 description 1
101710199711 Early E1A protein Proteins 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
108010067770 Endopeptidase K Proteins 0.000 description 1
241000709661 Enterovirus Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
101150064015 FAS gene Proteins 0.000 description 1
108010023321 Factor VII Proteins 0.000 description 1
108010039731 Fatty Acid Synthases Proteins 0.000 description 1
108090000331 Firefly luciferases Proteins 0.000 description 1
208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
208000031448 Genomic Instability Diseases 0.000 description 1
QZQYITIKPAUDGN-GVXVVHGQSA-N Gln-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCC(=O)N)N QZQYITIKPAUDGN-GVXVVHGQSA-N 0.000 description 1
LHYJCVCQPWRMKZ-WEDXCCLWSA-N Gly-Leu-Thr Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LHYJCVCQPWRMKZ-WEDXCCLWSA-N 0.000 description 1
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
101000768777 Haloferax lucentense (strain DSM 14919 / JCM 9276 / NCIMB 13854 / Aa 2.2) Uncharacterized 50.6 kDa protein in the 5'region of gyrA and gyrB Proteins 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
101000605528 Homo sapiens Kallikrein-2 Proteins 0.000 description 1
101000904152 Homo sapiens Transcription factor E2F1 Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
241000829111 Human polyomavirus 1 Species 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
101000607404 Infectious laryngotracheitis virus (strain Thorne V882) Protein UL24 homolog Proteins 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
101000735632 Klebsiella pneumoniae Uncharacterized 8.8 kDa protein in aacA4 3'region Proteins 0.000 description 1
108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
XWEVVRRSIOBJOO-SRVKXCTJSA-N Leu-Pro-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O XWEVVRRSIOBJOO-SRVKXCTJSA-N 0.000 description 1
ILDSIMPXNFWKLH-KATARQTJSA-N Leu-Thr-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O ILDSIMPXNFWKLH-KATARQTJSA-N 0.000 description 1
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
206010025538 Malignant ascites Diseases 0.000 description 1
UYDDNEYNGGSTDW-OYDLWJJNSA-N Met-Trp-Trp Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)O)N UYDDNEYNGGSTDW-OYDLWJJNSA-N 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
101710134502 Mgp-operon protein 3 Proteins 0.000 description 1
102000007298 Mucin-1 Human genes 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
101000844719 Mus musculus Deleted in malignant brain tumors 1 protein Proteins 0.000 description 1
101100117764 Mus musculus Dusp2 gene Proteins 0.000 description 1
102000005604 Myosin Heavy Chains Human genes 0.000 description 1
108010084498 Myosin Heavy Chains Proteins 0.000 description 1
108091061960 Naked DNA Proteins 0.000 description 1
208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
108020005497 Nuclear hormone receptor Proteins 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
101710087110 ORF6 protein Proteins 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
102000043276 Oncogene Human genes 0.000 description 1
108091006006 PEGylated Proteins Proteins 0.000 description 1
108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
JXQVYPWVGUOIDV-MXAVVETBSA-N Phe-Ser-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JXQVYPWVGUOIDV-MXAVVETBSA-N 0.000 description 1
GOUWCZRDTWTODO-YDHLFZDLSA-N Phe-Val-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O GOUWCZRDTWTODO-YDHLFZDLSA-N 0.000 description 1
102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
108010001014 Plasminogen Activators Proteins 0.000 description 1
102000001938 Plasminogen Activators Human genes 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
101710164463 Preterminal protein Proteins 0.000 description 1
241001415846 Procellariidae Species 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
208000004965 Prostatic Intraepithelial Neoplasia Diseases 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
108020005091 Replication Origin Proteins 0.000 description 1
241001068263 Replication competent viruses Species 0.000 description 1
108700025701 Retinoblastoma Genes Proteins 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
108010039491 Ricin Proteins 0.000 description 1
230000018199 S phase Effects 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
HRNQLKCLPVKZNE-CIUDSAMLSA-N Ser-Ala-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O HRNQLKCLPVKZNE-CIUDSAMLSA-N 0.000 description 1
NLOAIFSWUUFQFR-CIUDSAMLSA-N Ser-Leu-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O NLOAIFSWUUFQFR-CIUDSAMLSA-N 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
102000008145 Sodium-Potassium-Chloride Symporters Human genes 0.000 description 1
108010074941 Sodium-Potassium-Chloride Symporters Proteins 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
101000818100 Spirochaeta aurantia Uncharacterized 12.7 kDa protein in trpE 5'region Proteins 0.000 description 1
101001037658 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) Glucokinase Proteins 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
101000946719 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Carboxysome assembly protein CcmN Proteins 0.000 description 1
CAJFZCICSVBOJK-SHGPDSBTSA-N Thr-Ala-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAJFZCICSVBOJK-SHGPDSBTSA-N 0.000 description 1
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
101710138750 Transcription factor E2F1 Proteins 0.000 description 1
102000004338 Transferrin Human genes 0.000 description 1
108090000901 Transferrin Proteins 0.000 description 1
102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
108091061763 Triple-stranded DNA Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
GIAMKIPJSRZVJB-IHPCNDPISA-N Trp-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N GIAMKIPJSRZVJB-IHPCNDPISA-N 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
101710095001 Uncharacterized protein in nifU 5'region Proteins 0.000 description 1
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
208000002495 Uterine Neoplasms Diseases 0.000 description 1
108091008605 VEGF receptors Proteins 0.000 description 1
FEFZWCSXEMVSPO-LSJOCFKGSA-N Val-His-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](C)C(O)=O FEFZWCSXEMVSPO-LSJOCFKGSA-N 0.000 description 1
102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
238000010317 ablation therapy Methods 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
239000013543 active substance Substances 0.000 description 1
201000004484 acute conjunctivitis Diseases 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
230000006229 amino acid addition Effects 0.000 description 1
BIVUUOPIAYRCAP-UHFFFAOYSA-N aminoazanium;chloride Chemical compound Cl.NN BIVUUOPIAYRCAP-UHFFFAOYSA-N 0.000 description 1
230000003321 amplification Effects 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
239000000090 biomarker Substances 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
208000030270 breast disease Diseases 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000012761 co-transfection Methods 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
238000011026 diafiltration Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
238000013399 early diagnosis Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000009881 electrostatic interaction Effects 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000012202 endocytosis Effects 0.000 description 1
208000001991 endodermal sinus tumor Diseases 0.000 description 1
201000003908 endometrial adenocarcinoma Diseases 0.000 description 1
208000029382 endometrium adenocarcinoma Diseases 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
150000002118 epoxides Chemical class 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
229940012413 factor vii Drugs 0.000 description 1
230000008175 fetal development Effects 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000002825 functional assay Methods 0.000 description 1
230000004927 fusion Effects 0.000 description 1
IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
229960002963 ganciclovir Drugs 0.000 description 1
208000010749 gastric carcinoma Diseases 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
230000002710 gonadal effect Effects 0.000 description 1
239000005090 green fluorescent protein Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
108010040030 histidinoalanine Proteins 0.000 description 1
238000010562 histological examination Methods 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
238000001794 hormone therapy Methods 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
230000002390 hyperplastic effect Effects 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
238000010324 immunological assay Methods 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000002601 intratumoral effect Effects 0.000 description 1
230000009545 invasion Effects 0.000 description 1
239000012948 isocyanate Substances 0.000 description 1
201000010982 kidney cancer Diseases 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
101150066555 lacZ gene Proteins 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000003468 luciferase reporter gene assay Methods 0.000 description 1
239000006166 lysate Substances 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
229920001427 mPEG Polymers 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
210000005075 mammary gland Anatomy 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
210000004925 microvascular endothelial cell Anatomy 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
238000013188 needle biopsy Methods 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
210000000633 nuclear envelope Anatomy 0.000 description 1
102000006255 nuclear receptors Human genes 0.000 description 1
108020004017 nuclear receptors Proteins 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
238000011580 nude mouse model Methods 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
208000030352 pancreatic acinar cell carcinoma Diseases 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
229940055729 papain Drugs 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
244000052769 pathogen Species 0.000 description 1
101150027243 pb gene Proteins 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
150000004713 phosphodiesters Chemical class 0.000 description 1
PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
150000008298 phosphoramidates Chemical group 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
238000005498 polishing Methods 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
229920000768 polyamine Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920005606 polypropylene copolymer Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
238000010837 poor prognosis Methods 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000003825 pressing Methods 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
208000021046 prostate intraepithelial neoplasia Diseases 0.000 description 1
235000019419 proteases Nutrition 0.000 description 1
230000004853 protein function Effects 0.000 description 1
230000009145 protein modification Effects 0.000 description 1
238000012207 quantitative assay Methods 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
238000006722 reduction reaction Methods 0.000 description 1
102000037983 regulatory factors Human genes 0.000 description 1
108091008025 regulatory factors Proteins 0.000 description 1
238000009877 rendering Methods 0.000 description 1
BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000004044 response Effects 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
210000003079 salivary gland Anatomy 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
239000004017 serum-free culture medium Substances 0.000 description 1
150000004756 silanes Chemical class 0.000 description 1
239000002356 single layer Substances 0.000 description 1
238000001542 size-exclusion chromatography Methods 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000011255 standard chemotherapy Methods 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
201000000498 stomach carcinoma Diseases 0.000 description 1
239000000758 substrate Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
239000013589 supplement Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000001360 synchronised effect Effects 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
238000012385 systemic delivery Methods 0.000 description 1
230000008685 targeting Effects 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
108010061238 threonyl-glycine Proteins 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
238000004448 titration Methods 0.000 description 1
231100000167 toxic agent Toxicity 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
239000012581 transferrin Substances 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
238000003146 transient transfection Methods 0.000 description 1
230000007704 transition Effects 0.000 description 1
108091007466 transmembrane glycoproteins Proteins 0.000 description 1
108091005703 transmembrane proteins Proteins 0.000 description 1
102000035160 transmembrane proteins Human genes 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
238000011277 treatment modality Methods 0.000 description 1
230000005909 tumor killing Effects 0.000 description 1
239000000439 tumor marker Substances 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
108700026220 vif Genes Proteins 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
230000006648 viral gene expression Effects 0.000 description 1
210000000605 viral structure Anatomy 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
210000002845 virion Anatomy 0.000 description 1
108010047303 von Willebrand Factor Proteins 0.000 description 1
102100036537 von Willebrand factor Human genes 0.000 description 1
229960001134 von willebrand factor Drugs 0.000 description 1
238000001262 western blot Methods 0.000 description 1
210000001325 yolk sac Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Virology (AREA)
Wood Science & Technology (AREA)
Pharmacology & Pharmacy (AREA)
Zoology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Mycology (AREA)
Immunology (AREA)
Cell Biology (AREA)
Hematology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

CA002283231A 1997-03-03 1998-03-03 Vecteurs d'adenovirus contenant des elements heterologues regulateurs de transcription, et leur procede d'utilisation Expired - Lifetime CA2283231C (fr)

Applications Claiming Priority (9)

Application Number	Priority Date	Filing Date	Title
US3976397P	1997-03-03	1997-03-03
US3976297P	1997-03-03	1997-03-03
US60/039,762		1997-03-03
US60/039,763		1997-03-03
US5452397P	1997-08-04	1997-08-04
US60/054,523		1997-08-04
US09/033,556 US6432700B1 (en)	1997-03-03	1998-03-02	Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
US09/033,556		1998-03-02
PCT/US1998/004080 WO1998039464A2 (fr)	1997-03-03	1998-03-03	Vecteurs d'adenovirus contenant des elements heterologues regulateurs de transcription, et leur procede d'utilisation

Publications (2)

Publication Number	Publication Date
CA2283231A1 CA2283231A1 (fr)	1998-09-11
CA2283231C true CA2283231C (fr)	2008-05-20

Family

ID=27488125

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002283231A Expired - Lifetime CA2283231C (fr)	1997-03-03	1998-03-03	Vecteurs d'adenovirus contenant des elements heterologues regulateurs de transcription, et leur procede d'utilisation

Country Status (5)

Country	Link
EP (1)	EP1007715A2 (fr)
JP (1)	JP2002514074A (fr)
AU (1)	AU744725B2 (fr)
CA (1)	CA2283231C (fr)
WO (1)	WO1998039464A2 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0968298A2 (fr) *	1997-03-03	2000-01-05	Calydon, Inc.	Vecteurs d'adenovirus specifiques de cellules exprimant l'antigene carcino-embrionnaire et leurs methodes d'utilisation
DE69838584T2 (de)	1997-08-04	2008-06-26	Cell Genesys, Inc., Foster City	Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung
AU4070499A (en)	1998-04-30	1999-11-16	Cornell Research Foundation Inc.	Adenoviral vectors with tandem fiber proteins
US6900049B2 (en)	1998-09-10	2005-05-31	Cell Genesys, Inc.	Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US6455314B1 (en)	1998-09-11	2002-09-24	Genvec, Inc.	Alternatively targeted adenovirus
US6406861B1 (en)	1998-10-07	2002-06-18	Cell Genesys, Inc.	Methods of enhancing effectiveness of therapeutic viral immunogenic agent administration
IL142337A0 (en) *	1998-10-15	2002-03-10	Canji Inc	Selectively replicating viral vectors
AU6497799A (en) *	1998-10-15	2000-05-01	Canji, Inc.	Methods and compositions to induce antitumor response
US7691370B2 (en)	1998-10-15	2010-04-06	Canji, Inc.	Selectivity replicating viral vector
US6649158B1 (en)	1998-10-15	2003-11-18	Canji, Inc.	Methods and compositions to induce antitumor response
US6495130B1 (en)	1998-12-30	2002-12-17	Calydon, Inc.	Target cell-specific adenoviral vectors containing E3 and methods of use thereof
GB9906815D0 (en) *	1999-03-24	1999-05-19	Isrec	Anti-neoplastic viral agents
WO2001073093A2 (fr) *	2000-03-24	2001-10-04	Cell Genesys, Inc.	Vecteurs adenoviraux a specificite cellulaire comprenant un site recepteur interne du ribosome
EP1318839A2 (fr) *	2000-03-24	2003-06-18	Cell Genesys, Inc.	Methodes de traitement de la neoplasie avec des adenovirus specifiques des cellules cibles associes a la chimiotherapie et a la radiotherapie
US6911200B2 (en)	2000-03-24	2005-06-28	Cell Genesys, Inc.	Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation
US6692736B2 (en)	2000-03-24	2004-02-17	Cell Genesys, Inc.	Cell-specific adenovirus vectors comprising an internal ribosome entry site
US7048920B2 (en)	2000-03-24	2006-05-23	Cell Genesys, Inc.	Recombinant oncolytic adenovirus for human melanoma
US6673614B2 (en)	2000-06-27	2004-01-06	Cell Genesys, Inc.	Rapid methods and kits for detection and semi-quantitation of anti-adenovirus antibody
IL155154A0 (en) *	2000-09-30	2003-10-31	Diversa Corp	Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating
US7109029B2 (en)	2001-02-23	2006-09-19	Cell Genesys, Inc.	Vector constructs
GB0117198D0 (en) *	2001-07-13	2001-09-05	Btg Int Ltd	Anti-neoplastic viral agents
AU2003287451A1 (en)	2002-11-01	2004-06-07	Cell Genesys, Inc.	Cell-specific adenovirus vector comprising ebv-specific promoter
JP2007500012A (ja) *	2003-02-24	2007-01-11	セルジェネシスインコーポレイテッド	腫瘍溶解ウイルス複製の外部制御のためのシステム
US7482156B2 (en)	2003-10-15	2009-01-27	Cell Genesys, Inc.	Hepatocellular carcinoma specific promoter and uses thereof
US7473418B2 (en)	2004-03-25	2009-01-06	Cell Genesys, Inc.	Pan cancer oncolytic vectors and methods of use thereof
WO2011043719A1 (fr) *	2009-10-05	2011-04-14	Ya-Fang Mei	Réplication de vecteurs viraux pour thérapie génique
WO2017156349A1 (fr)	2016-03-10	2017-09-14	Cold Genesys, Inc.	Méthodes de traitement de tumeurs solides ou lymphatiques par polythérapie
EP4599893A3 (fr)	2017-04-14	2025-11-05	CG Oncology, Inc.	Cg0070 pour le traitement in situ du carcinome de la vessie résistant à bcg

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6093699A (en) *	1987-07-09	2000-07-25	The University Of Manitoba	Method for gene therapy involving suppression of an immune response
US6337209B1 (en) *	1992-02-26	2002-01-08	Glaxo Wellcome Inc.	Molecular constructs containing a carcinoembryonic antigen regulatory sequence
GB9216851D0 (en) *	1992-08-07	1992-09-23	Univ Manitoba	Dna sequences of rat probasin gene
US5698443A (en) *	1995-06-27	1997-12-16	Calydon, Inc.	Tissue specific viral vectors
ES2258265T3 (es) *	1994-11-28	2006-08-16	Cell Genesys Inc.	Vectores de replicacion con especificidad tisular.
AU4690596A (en) *	1994-12-30	1996-07-24	Chiron Viagene, Inc.	Nucleic acid condensing agents with reduced immunogenicity
US20030026789A1 (en) *	1995-05-03	2003-02-06	Richard J. Gregory	Gene therapy using replication competent targeted adenoviral vectors

1998
- 1998-03-03 EP EP98907702A patent/EP1007715A2/fr not_active Ceased
- 1998-03-03 CA CA002283231A patent/CA2283231C/fr not_active Expired - Lifetime
- 1998-03-03 JP JP53867498A patent/JP2002514074A/ja not_active Ceased
- 1998-03-03 WO PCT/US1998/004080 patent/WO1998039464A2/fr not_active Ceased
- 1998-03-03 AU AU63450/98A patent/AU744725B2/en not_active Expired

Also Published As

Publication number	Publication date
EP1007715A2 (fr)	2000-06-14
AU6345098A (en)	1998-09-22
JP2002514074A (ja)	2002-05-14
CA2283231A1 (fr)	1998-09-11
WO1998039464A3 (fr)	1999-01-07
AU744725B2 (en)	2002-02-28
WO1998039464A2 (fr)	1998-09-11
WO1998039464A8 (fr)	1999-04-01

Legal Events

Date	Code	Title	Description
2003-02-27	EEER	Examination request
2018-05-07	MKEX	Expiry	Effective date: 20180305

Publication	Publication Date	Title
CA2283231C (fr)	2008-05-20	Vecteurs d'adenovirus contenant des elements heterologues regulateurs de transcription, et leur procede d'utilisation
EP0972063B1 (fr)	2008-01-30	VECTEURS D'ADENOVIRUS SPECIFIQUES DE CELLULES EXPRIMANT LA FETOPROTEINE $g(a), ET LEURS MODES D'UTILISATION
AU762940B2 (en)	2003-07-10	Adenovirus vectors containing cell status-specific response elements and methods of use thereof
EP1017836B1 (fr)	2006-05-24	Vecteurs d'adenovirus specifiques de cellules exprimant le recepteur de l'androgene et leurs methodes d'utilisation
EP1141363B1 (fr)	2007-07-25	Vecteurs et transgenes ayant des elements regulateurs pour l'administration de genes dans le foie
US20030044383A1 (en)	2003-03-06	Tissue specific adenoviral vectors
US7001764B2 (en)	2006-02-21	Compositions comprising tissue specific adenoviral vectors
WO1998039467A2 (fr)	1998-09-11	Vecteurs d'adenovirus specifiques de cellules exprimant l'antigene carcino-embrionnaire et leurs methodes d'utilisation
US7011976B1 (en)	2006-03-14	Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
AU2003252891B2 (en)	2006-06-01	Adenovirus vectors containing cell status-specific response elements and methods of use thereof
EP1905837A1 (fr)	2008-04-02	Vecteurs d'adénovirus contenant des éléments hétérologues régulateurs de la transcription et procédés les utilisant
AU745600B2 (en)	2002-03-21	Adenovirus vectors specific for cells expressing carcinoembryonic antigen and methods of use thereof
US20020068049A1 (en)	2002-06-06	Tissue specific adenoviral vectors
US20060165658A1 (en)	2006-07-27	Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
EP1918380A2 (fr)	2008-05-07	Vecteurs d'adénovirus spécifiques de cellules exprimant la fétoprotéine alfa, et leur modes d'utilisation
US20060024273A1 (en)	2006-02-02	Target cell-specific adenoviral vectors containing E3 and methods of use thereof
EP0968298A2 (fr)	2000-01-05	Vecteurs d'adenovirus specifiques de cellules exprimant l'antigene carcino-embrionnaire et leurs methodes d'utilisation